

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16  
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2019

Commission File Number: 001-36582

**Auris Medical Holding Ltd.**  
(Exact name of registrant as specified in its charter)

Clarendon House, 2 Church Street  
Hamilton HM 11, Bermuda  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

## **Annual General Meeting Results**

On May 8, 2019, Auris Medical Holding Ltd. (the “**Company**”) held its Annual General Meeting of Shareholders (the “**Meeting**”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

### **Agenda Item 1: Re-election of the members of the Board of Directors.**

The Company’s shareholders re-elected Thomas Meyer, PhD, Armando Anido, MBA, Mats Peter Blom, MBA, Calvin W. Roberts, MD and Alain Munoz, MD, as member of the Board of Directors, each for a term of one year ending upon completion of the 2020 Annual General Meeting.

### **Agenda Item 2: Re-election of the Auditors**

The Company’s shareholders re-elected Deloitte AG, Switzerland, as auditors of Auris Medical Holding Ltd. for the 2019 financial year.

### **Agenda Item 3: Compensation of the Board of Directors and the Executive Management Committee**

The Company’s shareholders approved, on a non-binding advisory basis, the 2018 Board of Directors and executive officers compensation.

### **Other Items**

At the Meeting, the Chairman informed the shareholders that going forward the Company, as a Foreign Private Issuer pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), intends to file financial reports on a semi-annual instead of a quarterly basis in compliance with such SEC rules. The next financial statements will therefore be filed for the first six months ended June 30, 2019.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Auris Medical Holding Ltd.**

By: /s/ Hernan Levett

Name: Hernan Levett

Title: Chief Financial Officer

Date: May 8, 2019